Needham analyst David Saxon has maintained their neutral stance on XRAY stock, giving a Hold rating on July 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Saxon has given his Hold rating due to a combination of factors including the recent CEO transition at DENTSPLY SIRONA and the company’s preannounced financial results for the second quarter of 2025. The company reported revenue and earnings per share that slightly exceeded consensus estimates, but its overall financial guidance for 2025 indicates a decline in organic revenue. The appointment of Dan Scavilla as CEO, who has a track record of driving growth and profitability, is a positive development, yet it may take time for his impact to be fully realized.
Furthermore, the reaffirmation of financial guidance suggests stability, but the anticipated decline in organic revenue growth raises caution. The Hold rating reflects a wait-and-see approach, as the full impact of the new leadership and strategic direction will become clearer after the complete second-quarter results are available. Saxon appears to be balancing optimism about the new leadership with caution regarding the company’s current financial trajectory.
In another report released on July 16, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $16.50 price target.